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There is a need for studies on colonic fermentation in order to learn more about health and diseases of 
the colon. The aim of the present study was to evaluate the fate of two different doses of fructo- 
oligosaccharides (5 and 15 g/d) v. glucose in the intestine of healthy men. Twenty-four volunteers 
participated in a 5-week study. The study was a completely balanced multiple crossover trial using an 
orthogonal Latin-square design for three periods, with supplement periods of 7 d and two 7 d wash-out 
periods. Breath samples and faecal samples were collected. There was a clear gaseous response to the 
consumption of fructo-oligosacehandes. The highest dose significantly increased 24 h integrated 
excretion of breath H2 (P < 0.05). Breath H, excretion after ingestion of 5 g fructo-oligosaccharides was 
higher than control, but did not reach significance. No effects on the total concentration of short-chain 
fatty acids in faeces were observed, no modification of the molar proportions of the various short-chain 
fatty acids was observed. The faecal pH did not change. No changes in faecal weight were observed. No 
fructo-oligosaccharides were recovered in faeces. We conclude that fructo-oligosaccharides added to the 
diet of young Western subjects are fully metabolized in the large intestine. The level of fermentation 
seems to be dose-dependent. 
Fructo-oligosaccharides : Colon: Short-chain fatty acids: Breath hydrogen 
Studies on the effects of non-digestible oligosaccharides in elderly Japanese subjects suggest 
that dietary supplementation with fructo- or galacto-oligosaccharides is beneficial to the 
large intestine (Hidaka et al. 1986; Masai et al. 1987; Mitsuoka et al. 1987; Hayakawa 
el a!. 1990; Ito et al. 1990). The studies show a higher activity of the colonic microflora 
in response to the consumption of oligosaccharides, as demonstrated by increased 
fermentation. During carbohydrate fermentation, gases and shortchain fatty acids are 
formed (Cummings et al. 1987; Wang & Gibson, 1993). The production of short-chain fatty 
acids and the subsequent drop in colonic pH might protect against colonic cancer (Koo & 
Rao, 1991 ; van Munster et al. 1994). It is also suggested that oligosaccharides selectively 
stimulate bifidobacterial growth and thereby change the microfloral composition. Since 
bifidobacteria are considered to be beneficial genera, they may contribute to the 
establishment of a more healthy colonic environment (Mitsuoka, 1990; Modler et al. 1990; 
Gibson et a/. 1995). 
However, because the Japanese studies often lacked a strict study design or focused 
primarily on elderly people, we feel that they do not elucidate the metabolic fate of 
oligosaccharides in the large intestine. Also, observations made in Japan might not be 
applicable to populations with Western dietary patterns. Only a few studies have been 
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performed within Western populations so far and they have not investigated to what degree 
the oligosaccharides are fermentable (Stone-Dorshow & Levitt, 1987 ; Rumessen et al. 
1990a; Gibson et 01. 1995). Thus, we need more information to evaluate the fermentation 
process of oligosaccharides. 
The purpose of the present study was to examine the fate of fructo-oligosaccharides in 
the human intestine by studying several aspects of colonic fermentation in healthy young 
adults consuming a Western diet. The excretions of unfermented fructo-oligosaccharides 
and short-chain fatty acids in the faeces, and H, in the breath were measured. 
METHODS 
Subjects and experimental design 
Twenty-four healthy men aged 19-28 years volunteered to participate in the study. Women 
were excluded because of the possible influence of the menstrual cycle on fermentation 
(McBurney, 1991). All subjects had normal body weight (BMI 21-7 (SD 1.9) kg/m2), had no 
history of diabetes or gastrointestinal disease, and had not recently been treated with 
antibiotics or laxatives. They were not under any medication and blood screening tests were 
normal. None of the volunteers smoked. Four volunteers were vegetarians, none of the 
volunteers used a special diet. 
To avoid excess H being channelled into CH, production, subjects chosen were non-CH, 
producers. Three breath samples were collected on separate days, from each volunteer, 
before the study. Volunteers were classified as CH, excreters, when in one or more of the 
samples the CH, concentration exceeded 3 ppm above ambient air (Nagengast et al. 1988; 
Rumessen, 1992). Characteristics of the study population are given in Table 1. 
The study was a completely balanced multiple crossover trial using an orthogonal Latin- 
square design for three treatments, with supplement periods of 7 d and two 7 d wash-out 
periods between treatments. The volunteers consumed three different supplements in 
random order. At the end of the each supplement period faeces, breath and urine samples 
were collected. All subjects gave their informed written consent before participating. The 
study protocol was approved by the Ethical Committee of the Department of Human 
Nutrition, Wageningen Agricultural University. 
Supplements and food intake 
Diet composition was calculated in every supplement period from 2 d estimated records, 
using the 1986 release of The Netherlands nutrient data bank (Stichting Nederlands 
Voedingsstoffenbestand, 1986). Volunteers were asked to refrain from eating any fermented 
dairy products during the study. 
The supplements consisted of fructo-oligosaccharides (Raftilose P95 ; ORAFTI, Tienen, 
Belgium) and/or glucose (Cerestar Pur 01934; Cerestar Benelux BV, Sas van Gent, The 
Netherlands) in the following quantities : control, 0 g fructo-oligosaccharide + 4.1 g 
glucose; SF5, 5 g fructo-oligosaccharides + 2.7 g glucose; SF15, 15 g fructo-oligo- 
saccharides +O g glucose. They were dissolved in water and were of equal osmolarity. 
Supplements were consumed in split dose together with breakfast and dinner. To estimate 
stool recovery, thirty Ba-impregnated rings were swallowed daily together with the 
supplements and were counted afterwards in the faecal samples. 
A small dose (240,umol) of LiCl (Merck, Darmstadt, Germany) was added to each 
supplement.To check for compliance, the recovery of Li in 24 h urine was measured on the 
last 2 d of every supplement period (Sanchez-Castillo et al. 1987; van Houwelingen et al. 
1987; Leclercq et al. 1990). 
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Table 1. Characteristics and dietary intake of the subjects 
(Mean values and standard deviations for twenty-four male subjects) 
Mean SD 
Age (years) 22.1 2.1 
Weight (kg) 74.0 8.9 
Height (m) 1.85 0.10 
BMI (kg/m*) 21.7 1.9 
Energy intake (MJ) 13.7 3.6 
Fat intake (YO EI) 34.2 6.2 
Protein intake (YO EI) 12.1 1.8 
Carbohydrate intake (% EI) 50.4 7.4 
Dietary fibre (8) 39.7 11.9 
EI, energy intake. 
Data collection 
Body weight was measured on the first day of every supplement week, using electronic scales 
with a digital read-out to an accuracy of 0.05 kg (ED60-T; Berkel, Rotterdam, The 
Netherlands). 
During the whole study period, volunteers kept a diary. They recorded time of 
supplement consumption, time of defaecation, possible diseases or medication and 
deviations in eating, drinking or living behaviour. Stool form was rated for all stools on a 
5-point Likert scale which was based on the scale by Heaton et al. (1992) (watery; soft, 
pudding-like; soft, snake-like; dry, cylindric; dry, hard pellets). Gastrointestinal 
complaints concerning flatulence, bloating, abdominal pains or cramps, eructations, 
nausea, vomiting and stomach pains or cramps were rated on a 4-point Likert scale (none; 
mild; moderate; severe). 
Volunteers came to the Department of Human Nutrition twice at the end of each 
supplement period to defaecate. Within 15 min after defaecation the faeces were weighed 
and immediately deep-frozen on dry ice to stop fermentation, then stored at -20". 
On the last day of each supplement period, end-expiratory breath samples were taken at 
the Department of Human Nutrition at 4 h intervals from 08.00 hours (fasted) until 20.00 
hours and again at 08.00 hours (fasted) the next morning. Urine (24 h) was collected on the 
last 2 d  of every supplement period and 5ml glacial acetic acid was added to all urine 
bottles before collection as a preserving agent. 
Analytical procedures 
The 24 h urine samples were pooled when both collections were complete. Li was measured 
as described previously (Leclercq et al. 1990) using an atomic absorption spectrophotometer 
(Type 2380, Perkin-Elmer, Norwalk, CT, USA). Calibration was done with a standard 
concentration of 100 ,umol/l and with water as a blank. 
End-expiratory breath samples and ambient air samples were collected in plastic 60 ml 
syringes (Plastipak ; Becton Dickinson, Dublin, Ireland). CH, was measured in end- 
expiratory breath samples, using GC (Chrompack 438 AS; Hewlett Packard 427, 
Middelburg, The Netherlands). Calibration was done (daily) with 5 ppm and 29 ppm CH,- 
in-N, gases (Intermar b.v., Breda, The Netherlands). Within 2 h after collection the H, 
concentration was measured using a standard electrochemical cell (exhaled hydrogen 
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monitor ; Gas Measurement Instruments Ltd, Renfrew, Scotland). The cell was calibrated 
with a standard gas of 100 ppm H, in air (Intermar b.v.). 
All faecal samples were X-rayed before analysis to determine the number of Ba rings 
(Philips Optimus M200, Eindhoven, The Netherlands). Dry weight of the faeces was 
estimated by drying a portion for 4 d at 80” (Heraeus E45, Hanau, Germany). 
For the preparation of the aqueous fraction of stool the samples were thawed overnight 
at 4”. The two samples from each week were homogenized in a bowl and mixer. A portion 
was ultracentrifuged at 26000 g for 90 min at 4” (MSE, Scientific Instruments, Crawley, 
Sussex). Faecal water was carefully removed and stored at - 20” until analysis. The pH was 
measured in both faecal homogenate and faecal water with a digital pH meter (CD 620; 
WPA Ltd, Cambridge, Cambs.) 
Short-chain fatty acids were measured in faecal water as described by van Munster et al. 
(1994), using a Packard gas chromatograph (column: 10% SP1200/1% H,PO, on SO/lOO 
Chromosorb WAW, Hewlett Packard). The fructo-oligosaccharides present in faeces were 
determined in 0.25 g freeze-dried faeces. This was suspended in 5 ml water, vortex-mixed 
and boiled for 10 min. The suspension was centrifuged at 4500 rev./min for 25 min. The 
supernatant fraction was analysed by high-performance anion-exchange chromatography 
(Dionex b.v., Breda, The Netherlands). The system consisted of a gradient pump and 
programmable pulsed electrochemical detector. Separations were performed using a 
Carbopack PA-100 analytical column (4 x 250 mm, Dionex). The chromatographic mobile 
phase consisted of 0.1 M-NaOH (A) and 1 M-Na-acetate containing 0-1 M-NaOH (B). A 
linear gradient was used from 100 % A to 70 % A plus 30 % B in 25 min with a flow of 
1 ml/min. Samples were compared with spiked samples, containing three oligomers from 
Raftilose P95 (GF2, GF3 and GF4). The same HPLC method was used on undiluted urine 
samples for the detection of fructo-oligosaccharides in urine. 
Data analysis and statistics 
The 24 h integrated breath-H, excretion was estimated by calculating geometrically the 
area under the curve of concentration v .  time (Wolever & Jenkins, 1986). 
Results are expressed as means and standard errors, unless stated otherwise. The 
distributions of the differences between the three treatments were checked for normality by 
visual inspection of the normal probability plots. The significance of the differences 
between the three supplements in each subject was assessed by ANOVA without 
interactions (general linear models procedure). Because of a small number of missing values 
in the data set, leading to non-orthogonality of the model, the variable ‘period’ was added 
to the model. ‘Period’ did not contribute to the significance of the model, nor did it change 
any of the conclusions. Therefore the model used in the final analysis contained only 
‘subject’ and ‘treatment’. In cases of a significant difference (P < 0.05) between treatments, 
group means were tested with the Tukey or Scheffb tests. 
An exception to the given method of analysis was made for the breath H, data. Because 
of excessive numbers of missing values we used the least-square means statement to 
estimate mean values for each supplement and to evaluate differences between treatments 
in a model including ‘subject’, ‘period’ and ‘treatment’. This analysis accounts for unequal 
cell sizes; least-square means are estimators of the marginal means that would be expected 
had the design been balanced. 
The statistical analysis package SAS, version 6.09 (Statistical Analysis Systems Institute, 
Inc., Cary, NC, USA) was used to perform the statistical analyses. 
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RESULTS 
Supplements and food intake 
None of the volunteers experienced great difficulties with the consumption of the 
supplements. All volunteers completed the study successfully. The recovery of Li in urine 
was significantly lower (P < 0.05) after consumption of SF15 (82 %) than after 
consumption of control (90 %). The results of the 2 d food records obtained during each 
supplement period revealed no changes in the average daily intakes of energy, protein, fat, 
carbohydrates or dietary fibre. Mean values of dietary intakes from 6 d food records are 
given in Table 1. 
Diaries 
The information from the diaries is presented in Table 2. Gastrointestinal complaints 
concerning flatulence were significantly higher (P < 0.001) during consumption of SFl5 
compared with the control supplement. Although flatulence did not rise significantly during 
SF5, there was a visible trend towards a higher level. All other symptom scores were low 
and equal for the three supplements. 
There were no differences in recorded stool form between control and SF5. During SF15, 
stool form was rated somewhat lower and was more watery. This decrease, however, was 
not significant. No differences were found in frequency of defaecation between the 
supplements. 
Colonic fermentation 
Because of a technical defect of the exhaled H, monitor in the last week of the experiment, 
we only obtained sixteen observations of H, excretion (instead of twenty-four) in each 
supplement group. Fig. 1 shows the mean breath H, curve for each supplementation. When 
comparing the separate H, levels at different times we observed a significantly higher 
response (P < 0.01) at 12.00 hours for SF15. 
Table 3 summarizes the fermentation data. When expressing the H, excretion as the area 
under the H,-time curve (AUC) there was an increase in AUC from control (682 ppm.h) 
to SF5 (714 ppm.h; P = 078, compared with control) and to SF15 (986 ppm.h; P < 005 
compared with control). 
No changes in faecal weight were observed. The observed difference in wet weight 
between control and SF15 (or SF5) did not vary in any systematic way over the range of 
measurements. There was no significant correlation between differences in wet weight in 
response to supplementation and average values of wet weight (for SF5: Y - 0.03 ; P = 0.89, 
for SF15: r -0.26; P = 026). Four observations were excluded from the analysis of wet 
weight because volunteers had forgotten to swallow all Ba rings in that week, making it 
impossible to estimate daily productions. 
Faecal dry weight, expressed as a percentage of wet weight, did not change in response 
to the supplementation. No traces of the fructo-oligosaccharides that were provided in the 
supplement were recovered in any of the faecal samples. Figure 2 gives an example of a 
typical HPLC elution pattern for a faecal sample from one of the volunteers during SF15. 
Response A is Raftilose P95, response B is the sample spiked with the Raftilose P95 
oligomers GF2, GF3 and GF4, response C is the unspiked sample. 
In addition to faecal analyses, we also analysed urine samples for fructo-oligosaccharides. 
In none of the samples were any fructo-oligosaccharides detected. 
Concentrations of short-chain fatty acids were measured in faecal water. No 
accumulation of these fermentation products was observed. As shown in Fig. 3, the relative 
contributions of different short-chain fatty acids did not change. The pH values of faecal 
water and homogenate were not altered in response to the different supplements. Because 
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Table 2. Efect of dietury supplementation with 0 (control), 5 (SF5) or 15 (SF15) g fructo- 
oligosaccharidesld on gastrointestinal complaints, stool form and frequency of defaecationt 
(Mean values with their standard errors for twenty-four subjects) 
Abdominal pains Frequency of 
Flatulence$ Bloating3 or crampsf Stool form5 defaecationll 
Mean SE Mean SE Mean SE Mean SE Mean SE 
Supplement : 
Control 0 5  0 1  0.1 0.1 00 0.0 3 3  0.1 1-2 0 1  
SFS 0.7 0 1  0.1 0.1 0.0 0.0 3.2 0.2 1.3 0.1 
SF15 1.0*** 01 0.2 0.1 0.1 0.0 3.1 0.1 1.2 0.1 
df MSE 46 46 46 46 46 
Supplement P < 0.001 NS NS NS NS 
Subject P 4 0~0001 P 4 0~0001 NS P 4 0.0001 P 4 0.0001 
SF5-control 0 2  0 1  0.0 0.0 -0.0 0.0 -0.0 0.1 0.1 0.1 
SFlS-control 0 4  0 1  0.1 0.0 0.1 0.0 -0.1 0.1 0.1 0.1 
df, Degrees of freedom; MSE, mean square error. 
*** Mean value was significantly different from control, P c 0,001. 
t For details of subjects and procedures, see Table 1 and pp. 212-214. 
$ Subjects scored symptoms on a scale from 0 (none) to 3 (severe). Symptom scores for eructations, nausea, 
9: Stool form was rated on a scale from 1 (watery) to 5 (dry, hard pellets). 
11 Mean frequency per day in each supplement week. 
Analysis of variance : 
Differences : 
vomiting and stomach pains or cramps were zero for all supplements. 
Time of day (hours) 
Fig. 1. Least-square means (LS Means) of breath hydrogen concentrations (ppm) at  regular time intervals on the 
seventh day of supplementation with 0 (m), S (A) or 15 g (0) fructo-oligosaccharides. LS Means are based on 
sixteen observations for each plotted point. (m) Time of supplement ingestion. * P c 0.01 in comparison with 
control. 
there were three cases in which the amount of extractable faecal water was negligible, faecal 
short-chain fatty acids and pH of faecal water could not be measured for these 
observations. There was a significant negative correlation between the pH of faecal water 
and the total amount of short-chain fatty acids ( I  -0.57, P < 0.0001) as measured in faecal 
water. 
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Table 3 .  Eflect of dietary supplementation with 0 (control), 5 (SF5) or 15 (SF15) g fructo- 
oligosaccharidesld on breath hydrogen excretion, faecal weight, faecal p H  and short-chain 
fatty acid concentrations? 
(Mean values with their standard errors for twenty-four subjects) 
Short-chain 
Breath hydrogen Faecal wet wt Faecal dry wt fatty acids 
(PPm. h) 2 (g/d)§ (g/kg wet wt) Faecal pHlI (mmol/l)ll 
Mean SE Mean SE Mean SE Mean SE Mean SE 
Supplement: 
Control 682 80 212 26 245 9 6.5 0 1  151 7 
SF5 114 77 219 33 232 12 6.4 0 1  150 7 
SF15 986* 85 264 22 237 1 6.4 0 1  153 8 
df MSE 19 39 46 45 43 
Period NS 
Supplement P < 0.05 NS NS NS NS 
Subject P < 001 P < 0~0001 P < 0~0001 P < 0~0001 P < 0.01 
Analysis of variance: 
Differences : 
SFS-control 32 116 -32 20 -13 9 -0.1 0 1  -4 9 
SF15-control 304 120 -17 25 -8 8 0 0 1  3 1  
df, Degrees of freedom; MSE, mean square error. 
* Mean value was significantly different from control, P < 0.05. 
t For details of subjects and procedures, see Table 1 and pp. 212-214. 
$ Least-square means (LS Means) and standard errors of the LS Means; n 16 for each supplement group. 
Q Mean daily production as estimated from marker recovery. Four observations were excluded because markers 
1) As measured in faecal water. Three observations were missing because there was too little faecal water 
were not swallowed. 
extractable from faeces. 
A 
cw_ 
n 
J! - 
18 
& 
23 
Retention time (min) 
Fig. 2. Typical HPLC patterns for one of the volunteers. Samples were (A) Raftilose P95, (B) faecal sample after 
supplementation with fructo-oligosaccharides, spiked with three oligomers from Raftilose P95 (A ), (C) the same 
faecal sample, unspiked. 
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Total SCFA 
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SCFA in faecal water (mrnol/l) 
Fig. 3. Mean concentration of short-chain fatty acids (SCFA) as measured in faecal water obtained from two 
pooled stools, after 5-7 d of detary supplementatlon with 0 (m), 5 (El) or 15 g (1) fructo-oligosaccharides. 
DISCUSSION 
This study shows that fructo-oligosaccharides are completely fermented in the large 
intestine. 
Complete malabsorption in the small intestine was confirmed, since no fructo- 
oligosaccharides were detected in any of the urine samples, and it has been shown that 
fructo-oligosaccharides are not metabolized by human digestive enzymes in the small 
intestine (Oku et al. 1984; Nilsson & Bjorck, 1988; Tokunaga et al. 1989) and thus reach 
the large intestine. We demonstrated fermentation positively through the observed increase 
of breath H, excretion. This fermentation was complete, since no fructo-oligosaccharides 
were excreted in faeces during the last 2 d of each supplementation period. The present 
study is the first to show the complete fermentation of fructo-oligosaccharides in an in vivo 
experiment. 
The increase of H, excretion during fermentation of fructo-oligosaccharides has also 
been observed by other investigators (Stone-Dorshow & Levitt, 1987; Rumessen et al. 
1990a; Gibson et al. 1995). The level of breath H, excretion seems to be dose-dependent. 
During SF5 the excretion was higher than during the control period, although it did not 
reach significance. At the SF15 level the excretion of H, was significantly higher than 
during the control treatment. This dose effect was also observed by Rumessen et al. (1990a) 
using fructans, which are longer-chain oligomers. It is unlikely that the effect on H, 
excretion during SF5 was missed because of a rapid fermentation and short-lived increases 
of breath H,. The H, response to fructo-oligosaccharides might be rapid, but the 
concentration is shown to be elevated for at least 6 h after supplementation (Stone- 
Dorshow & Levitt, 1987). A more likely explanation for the very small difference between 
control and SF5 is that the effect was masked by the meal-related H, response. 
In the present study it was impossible to test for linearity, since we only tested three doses 
of fructo-oligosaccharides. However, in a study by Rumessen et al. (1990b) the excretion 
of H, in breath increased linearly with the consumption of up to 20 g lactulose. 
We did not find any increase in short-chain fatty acid concentration in faeces after 
supplementation with fructo-oligosaccharides and, consequently, no changes in the average 
pH values of faecal water. Short-chain fatty acids are mainly produced in the proximal 
colon where the amount of available substrates is highest (Macfarlane et al. 1992). Rapid 
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absorption by the colonic mucosa leads to a lower concentration in the faeces (Hoverstad 
et al. 1982; Cummings et al. 1987). This is probably the reason that we did not find the 
expected changes in short-chain fatty acids or pH. 
Our results were in accordance with the recent findings of Gibson et al. (1995) who 
published a study investigating the effects of fructo-oligosaccharides on large-bowel 
microflora and colonic function in a controlled feeding trial (n 8). They did not observe any 
major differences in faecal short-chain fatty acid concentration between supplementation 
with 15 g fructo-oligosaccharides or sucrose. In an experiment by Mitsuoka et al. (1987) the 
effects of fructo-oligosaccharides on intestinal microflora and faecal pH were evaluated. 
Elderly patients (n 23) participated in a 3-week experiment. They consumed 8 g fructo- 
oligosaccharides/d for 2 weeks. Faecal collection took place before, during and after 
administration. A mean decrease of faecal pH (by 0 3  units) was observed, but no 
information was given on variations or levels of significance. No control treatment was 
used. 
In the present study, supplementation with fructo-oligosaccharides, even at the SFl5 
level, did not cause changes in stool form, wet or dry weight of faeces or frequency of 
defaecation. Our findings on faecal mass were surprising. We expected that increased 
fermentation would lead to an increase of total microbial mass. As this microbial mass is 
estimated to be about 55 % of the total faecal solids, a faecal weight change was anticipated 
(Stephen & Cummings, 1980), Ito et al. (1990) investigated the effects of administering 
galacto-oligosaccharides on different variables. No changes in faecal weight were observed 
after testing different doses of galacto-oligosaccharides using a strict study design. Gibson 
et al. (1995) showed a trend towards higher faecal wet and dry weights. Since the excretion 
of N was significantly higher during supplementation with fructo-oligosaccharides, the 
authors concluded that the increase in faecal weight was probably due to an increase in 
biomass. Little effect was shown on total bacterial counts per gram faeces. The present 
study was performed under uncontrolled dietary conditions and therefore correction for 
dietary fibre intake was impossible. The bulking capacity of dietary fibre might have 
influenced the faecal weights in this study (Cummings et al. 1992) and possibly masked the 
effect of biomass on faecal weight. Moreover, it should be noted that fibre intakes were 
relatively high compared with the average intake by Dutch men of the same age category 
(40 gjd v. 27 g/d) (Ministerie van Welzijn & Ministerie van Landbouw en Visserij, 1988). 
This is also reflected in the daily stool output (mean 270 g/d) which is considerably higher 
than reported values for healthy male adults in the UK (mean 122 g/d; Cummings et al. 
1992). 
In general, the volunteers accepted the sweet taste of fructo-oligosaccharides well. The 
only negative remark concerned the increase in flatulence during SF1 5 supplements. 
The fructo-oligosaccharide supplements were marked with Li in order to check 
compliance of intakes. Li recovery was 82 YO during SF15, which was significantly lower 
than the 90 YO recovery during control. If this was due to a lower intake of SF1 5 then the 
intake of fructo-oligosaccharides at this level might not have been 15 g, but between 13.5 
and 14 g/d. This would still have been high compared with the estimated daily consumption 
of fructo-oligosaccharides, which is only about 1 g/d (Spiegel et al. 1994). 
We conclude that fructo-oligosaccharides added to the diet of young Western subjects 
are fully metabolized in the large intestine. The next step is to study in depth the specific 
effects of supplementation with fructo-oligosaccharides on microfloral growth and 
metabolism. Gibson et al. (1995) recently reported interesting results suggesting that 
supplementation with oligosaccharides might lead to the establishment of a more healthy 
colonic community, through the selective stimulation of bifidobacteria. 
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